Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection
Key facts
- Who runs it
- Liaquat University of Medical & Health Sciences
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 289 people enrolled
- Started
- 2 Jan 2023
- Ended
- 15 Dec 2024
- Type of study
- Observational, 3 groups
- Treatments tested
- AHCC® (Active Hexose Correlated Compound)
- Gardasil 9®
- Record updated
- 28 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Female participants aged 18 years or older
- Documented persistent high-risk HPV infection for at least 6 continuous months, confirmed by consecutive HPV-DNA tests
- Absence of high-grade cervical lesions (≤ CIN1)
- Availability of complete clinical records with evaluable HPV-DNA testing at baseline and follow-up
- Documented management with AHCC® supplementation alone, nonavalent HPV vaccination alone, or combined AHCC® supplementation and nonavalent HPV vaccination in routine clinical practice
- No prior excisional or ablative treatment of the cervix (including conization or LEEP)
Who cannot take part
- History of cervical excisional or ablative treatment (including conization or LEEP)
- Presence of high-grade cervical lesions (CIN2 or worse) or invasive cervical cancer
- Conditions known to significantly alter immune function, including ongoing immunosuppressive therapy, active autoimmune disease requiring systemic treatment, or documented immunodeficiency, when such information was available in medical records
- Prior systemic antiviral or immunomodulatory therapy specifically aimed at HPV clearance during the observation period
- Incomplete clinical documentation or missing HPV follow-up data
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a retrospective, multicenter, observational study evaluating real-world HPV-DNA clearance in women with documented persistent high-risk HPV infection lasting at least six months. Clinical data were retrospectively collected from medical records of women managed in routine practice with one of three strategies: AHCC® supplementation alone, nonavalent HPV vaccination alone, or the combination of AHCC® supplementation and nonavalent HPV vaccination. The primary objective is to assess HPV-DNA clearance at 4 and 6 months following treatment initiation.
The 3 groups in the trial
- Unvaccinated with AHCC® Supplement
Women previously managed in routine clinical practice with AHCC® supplementation alone for persistent HPV infection. Participants had not received HPV vaccination prior to treatment. Clinical data were retrospectively collected from medical records to evaluate HPV-DNA clearance following this real-world management strategy.
Treatment: AHCC® (Active Hexose Correlated Compound)
- Vaccinated with AHCC® Supplement
Women previously managed in routine clinical practice with combined AHCC® supplementation and nonavalent HPV vaccination for persistent HPV infection. Treatments were prescribed as part of standard care. Clinical data were retrospectively collected to assess HPV-DNA clearance following combined real-world exposure.
Treatment: AHCC® (Active Hexose Correlated Compound) and Gardasil 9®
- Vaccinated Only
Women previously managed in routine clinical practice with nonavalent HPV vaccination alone for persistent HPV infection. No AHCC® supplementation was used. Clinical data were retrospectively collected to assess HPV-DNA clearance following vaccination as standard care.
Treatment: Gardasil 9®
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Efficacy and Safety of an AHCC®-Based Supplement (Lentinula Edodes) in Promoting Negativity of Persistent HPV Infection: A Retrospective Multicenter Clinical Study
- Record updated
- 28 January 2026